Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers